For capital market enthusiasts, identifying entry points, hidden gems, and value bets is akin to discovering buried treasure. Among the stores of riches on offer are quality stocks hovering around their 52-week lows, presenting an enticing window of opportunity.
In the current landscape, attention is drawn to three stalwart companies with a combined $35 billion market capitalization. These titans are Starbucks Corp SBUX, Gilead Sciences GILD, and Ambev SA ABEV.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
Starbucks: A Percolating Opportunity
Priced around $86.83, the coffee giant’s stock beckons with a potential buy-the-dip prospect. With a market cap exceeding $98 billion and an average three-month trading volume of 8.49 million, Seattle’s pride is brewing a strong sip of potential.
Investors can relish a 2.63% dividend yield on their Starbucks shares.
Recent analyst ratings from Wells Fargo, TD Cowen, and TD Cowen forecast an average price target of $102.33 for Starbucks Corp, indicating a tantalizing 17.23% upside.
Gilead Sciences: A Pharma Elixir
Trades at approximately $69.32, this biopharma gem is currently hovering near its 52-week lows. Gilead enjoys acclaim for its groundbreaking antiretroviral drugs combating HIV/AIDS, including the market favorites Truvada, Atripla, and Descovy.
Investors in Gilead stock relish a robust 4.43% dividend yield.
Recent analyst ratings by Wells Fargo, Mizuho, and Truist Securities converge on an average price target of $83.33, portending a 20.16% upside for the company.
Ambev: Brewing Success
Ambev SA, celebrated for its enviable beer portfolio featuring iconic labels like Skol, Brahma, Antarctica, and Budweiser, is priced at $2.40, lurking around its 52-week low mark of $2.36. The stock offers a frothy dividend yield of 6.26% to its investors.
Based on the scrutiny of the 8 latest analyst ratings, Ambev SA emerges with a consensus price target of $2.2. Recent evaluations from Barclays, Jefferies, and Bernstein predict an average price target of $3.2 for Ambev stock, signaling a glittering 32.51% potential upside.
These insights paint a portrait of quality stocks ripe with promising investment prospects, teeming with potential gains for astute investors venturing into the market.